We use our proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. We are leveraging our proprietary SNIPRx platform to discover, validate and build a robust pipeline of SL-based therapeutics. Our current pipeline is represented in the diagram below.
For information regarding our Study of RP-3500 in Advanced Solid Tumors click here.
For partnership and business development contact us at: firstname.lastname@example.org.
For medical information contact us at: email@example.com.